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Abstract
Resistance to available therapeutic agents has been a common problem thwarting progress in treatment of castrate-
resistant and metastatic prostate cancer (PCa). Overexpression of the Bcl-2 family members, including Mcl-1, in
PCa cells is known to inhibit intracellular mitochondrial-dependent apoptosis. Here we report the development of a
novel transgenic mouse model that spontaneously develops prostatic intraepithelial neoplasia and adenocarcinoma
by the inducible, conditional knockout of transforming growth factor β receptor type II in stromal fibroblastic cells
(Tgfbr2ColTKO). The Tgfbr2ColTKO prostate epithelia demonstrated down-regulation of luminal and basal differentiation
markers, as well as Pten expression and up-regulation of Mcl-1. However, unlike in men, Tgfbr2ColTKO prostates
exhibited no regression acutely after castration. The administration of Sabutoclax (BI-97C1), a pan-active Bcl-2 protein
family antagonist mediated apoptosis in castrate-resistant PCa cells of Tgfbr2ColTKO mice and human subcutaneous,
orthotopic, and intratibial xenograft PCa models. Interestingly, Sabutoclax had little apoptotic effect on benign pros-
tate tissue in Tgfbr2ColTKO and wild-type mice. Sabutoclax was able to block c-Met activation, a critical axis in PCa
metastatic progression. Further, Sabutoclax synergistically sensitized PC-3 cells to the cytotoxic effects of docetaxel
(Taxotere). Together, these data suggest that Sabutoclax inhibits castrate-resistant PCa alone at the primary and bone
metastatic site as well as support sensitivity to docetaxel treatment.
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Introduction
Prostate cancer (PCa) remains the second leading cause of cancer-
related death among American men [1]. Traditional therapy for PCa
has not changed substantially over the last few decades in that surgical
removal of the prostate (prostatectomy) remains the basis for pri-
mary PCa treatment. Ablative radiation therapies and cytotoxic chemo-
therapeutic agents in numerous clinical trials and in practice have an
overall limited treatment efficacy [2]. Androgen-deprivation therapy
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after prostatectomy of primary PCa, although generally efficacious in
the short term, fails when a subset of the carcinoma cells becomes
castrate-resistant (insensitive to withdrawal of androgen and/or andro-
gen signaling blockade by administration of androgen antagonists,
such as bicalutamide) [3]. The generation of new molecularly targeted
therapies is required to improve PCa patient care, treatment, and
prognosis. Evasion of apoptosis (programmed cell death to prevent un-
controlled growth) is a known hallmark of cancer progression and a
means by which cancers develop resistance to chemotherapeutic treat-
ments [4]. Castrate-resistant PCa (CRPC) may be overcome by either
sensitizing cancer cells to apoptotic stimuli or circumventing upstream
blockages in apoptotic signaling [5,6]. Such restoration of apoptosis in
PCa cells would counterbalance the proliferative and invasive burdens
imposed on the host by localized primary and disseminated metastatic
tumor cells.
Analyses of human prostate tumors over the last decade have shed
much light on the molecular factors and mechanisms contributing
to PCa initiation and progression. Loss of at least one allele of PTEN,
and hence reduction or loss of expression of the PTEN protein, fre-
quently occurs in up to 70% of human PCa specimens and consid-
ered a contributing factor in CRPC [7,8]. The unrestrained PI3K/
AKT antiapoptotic activity caused by the loss of PTEN expression
is also attributed to CRPC development of Pten knockout mice
[9]. Insensitivity to transforming growth factor β (TGF-β) is also
commonly observed and is mediated in human PCa by hetero-
geneous loss of type II TGF-β receptor expression in stromal fibro-
blastic cells [10]. Knockout of the gene encoding type II TGF-β
receptor (Tgfbr2) in prostate stromal fibroblasts in Tgfbr2fspKO mice
resulted in the development of prostatic intraepithelial neoplasia (PIN)
lesions and subsequent prostate adenocarcinoma [10,11]. This loss
of stromal TGF-β responsiveness in Tgfbr2fspKO mice led to CRPC
progression associated with elevated stromal release of proproliferative
cytokines including hepatocyte growth factor (HGF) [11,12] and
Wnts [10], proinflammatory cytokines including CCL2 [13], and
proinvasive cytokines such as SDF-1 [14,15]. Similar induction of
cytokine secretion by the stromal cells has been reported in studies of
Tgfbr2fspKO mammary gland tumors [12,16,17]. However, the early
lethality of Tgfbr2fspKO model limited prostate tumor progression analy-
sis. Here, we describe the development of novel prostate adenocarcinoma
model with an inducible stromal fibroblastic knockout of Tgfbr2, with
viability allowing for testing of therapeutic targets.
Overexpression of Mcl-1 is frequently associated with advanced
human PCa (high-Gleason-grade primary tumors and metastases)
[18], as well as other carcinomas and leukemia [19]. Mcl-1 is a highly
regulated antiapoptotic member of the Bcl-2 protein family known to
antagonize the function of many proapoptotic BH and BH3-only
proteins [20]. Elevated expression of Bcl-2 family of proteins is a key
mechanism resulting in evasion of mitochondrial-dependent apop-
tosis by cancer cells [19]. Previous studies from our laboratories and
from others [21–23] have reported that the natural product Gossypol
is a potent inhibitor of Bcl-2, Bcl-XL and Mcl-1, functioning as a
BH3 mimic, is currently in clinical trials, displaying single-agent anti-
tumor activity in patients with advanced malignancies [22]. However,
we anticipated that the two reactive aldehyde groups could render
Gossypol intrinsically toxic and was thus eliminated to lead to the com-
pound Apogossypol [24–26]. Further modifications on Apogossypol
were made to improve potency and efficacy [27]. These studies culmi-
nated in Sabutoclax [27,28], with increased potency in vitro against
Bcl-2 family proteins [28–30]. Here we report the use of Sabutoclax
(SBX, also known as BI-97C1) to inhibit prostate tumor progression.
We used multiple PCa models to specifically test late stage disease that
can involve castrate resistance, bone metastasis, and docetaxel resistance.
In our studies, Sabutoclax caused the regression of CRPC transgenic
and xenograft models at both primary and bone microenvironments.
A mediator of PCa castrate resistance and metastasis, the HGF/c-Met
signaling, was downregulated by Sabutoclax treatment in in vitro and
in vivo models. Sabutoclax restored sensitivity of PCa epithelial cells
to intracellular apoptotic signaling, both alone and with docetaxel,
resulting in substantial reduction in tumor progression.
Materials and Methods
In Vivo Efficacy Testing of Sabutoclax in Xenograft and
Transgenic Mouse Models of PCa
The Tgfbr2ColTKO mice (C57BL/6) express a tamoxifen-inducible
Cre recombinase under the control of a COL1A2 proximal pro-
moter [31]. Intraperitoneal (ip) injection of tamoxifen (1 mg dose in
90% vegetable oil and 10% ethanol vehicle; Sigma-Aldrich, St Louis,
MO) in lactating dams induced Cre-mediated fibroblastic Tgfbr2
conditional knockout of nursing pups (1, 3, and 5 days postpartum).
Recombination of the Tgfbr2 locus was confirmed at 3 weeks of age
by genotyping polymerase chain reaction (PCR) as previously de-
scribed [11]. Genotyping for Cre, floxed Tgfbr2, and Rosa26 were
performed by PCR using primers as described [12]. Tgfbr2ColTKO
(36 weeks old) and control C57BL/6 male mice were treated ip with
Sabutoclax (5 mg/kg) or phosphate-buffered saline (PBS) vehicle three
times per week.
A subcutaneous tumor model was established by injecting 8- to
10-week-old male Balb/c Nu/Nu nude mice subcutaneously with 2 ×
106 C4-2 human PCa cells per site (four sites/mouse). The C4-2 cells
were routinely cultured as previously described [32], harvested by tryp-
sinization, and suspended in sterile PBS for injection. When tumors
were visible (day 20), Sabutoclax (5 mg/kg) or vehicle were injected
ip every other day for 1 week. Body weights and tumor volumes were
measured before each injection. Data were expressed as relative ratios
to day 0 (the day drug injection was initiated).
A prostatic bone growth model was established by intratibial in-
jection of 1 × 106 ARCaPM-luc (luciferase expressing) PCa epithelia
suspended in PBS into both legs of male Nu/Nu nude mice. The
ARCaPM cells were cultured as previously described [33]. A week
after injection, the mice were treated with vehicle or with 2.5 mg/kg
of Sabutoclax ip for 5 days. Tumor progression was measured using
luciferase imaging on a Xenogen system (Caliper, Hopkinton, MA).
In vivo efficacy studies for Sabutoclax and docetaxel, as single agents
and in combination, were conducted by subcutaneously implanting
PC-3 cells (2 × 106) in the hind flank of male athymic nude mice using
100 μl of a 50:50 solution of Matrigel and RPMI-1640 media. Tumor
growth was monitored until it reached a mean tumor volume of 150
to 200 mm3 at which point the mice were distributed into groups of six
animals each. Sabutoclax was dosed at 2, 5, or 10 mg/kg intravenously
three times weekly. Docetaxel was administered at 12.5 mg/kg ip once
weekly. Tumor volumes were measured in two dimensions and deter-
mined by the formula of w × h2 × 1/2. Animal body weights were
tracked throughout the experiment.
Institutional Animal Care and Use Committees of Vanderbilt Uni-
versity, Sanford-Burnham Medical Research Institute, and Cedars-
Sinai Medical Center approved all animal procedures.
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In Vitro Synergy Analysis of Sabutoclax and Docetaxel in
PC-3 Cells
PC-3 cells were grown in RPMI-1640 medium containing 5 mM
Glutamax (Invitrogen, Grand Island,NY) supplemented with 10% fetal
bovine serum (Invitrogen) and 1× antibiotic/antimycotic (Invitrogen) at
37°C in a humidified incubator with 5%CO2. Cells were maintained at
40% to 80% confluence for a minimum of two passages before testing.
The activity of the compounds individually and in combination was
determined using the ATP-Lite 1-Step assay (PerkinElmer, Waltham,
MA). Cells were seeded in 96-well plates flat-bottom white plates
(Greiner, Monroe, NC) at a density of 5000 cells per well in RPMI-
1640 medium with 5 mM Glutamax (Invitrogen) supplemented with
5% fetal bovine serum (Invitrogen) and 1× antimitotic/antimycotic
(Invitrogen). After 24 hours, the medium was removed, and fresh
RPMI-1640 medium, supplemented as above, was added. At this time,
cells were treated with Sabutoclax (dose range of 30-3000 nM) and/or
docetaxel (dose range of 0.3-300 nM). Each treatment was performed
in triplicate with a final dimethyl sulfoxide (DMSO) concentration of
0.3%. For synergy analyses, a constant Sabutoclax/docetaxel ratio of
10:1 was established across the dosing range. Each sample plate was in-
cubated at 37°C in a 5% CO2 environment for 72 hours. Cell viability
was evaluated using ATP-LITE reagent (PerkinElmer), and lumines-
cence measurements were obtained on a Victor 2030 Explorer plate
reader (PerkinElmer). Data were normalized to DMSO control-treated
cells, and ED50 values were calculated using GraphPad Prism 5.2
(GraphPad Software, Inc). The synergy tests were performed three
times, and all data represent the mean ± SEM of tests. Combination
index (CI) values for quantification of synergy were calculated using
CalcuSyn (Biosoft, Cambridge, United Kingdom).
Immunohistochemistry
Histochemical staining was performed on mouse tissue that was fixed
with either 4% paraformaldehyde or 10% neutral buffered formalin,
paraffin-embedded, and sectioned (5 μm thick), essentially as described
[10]. After antigen retrieval, using 1:100 diluted antigen unmasking
solution (Vector Laboratories, Burlingame, CA), the sections were incu-
bated sequentially with primary antibody (overnight) and visualized
using appropriate horseradish peroxidase–conjugated secondary antibody
systems (Dako, Carpinteria, CA). Antibodies and concentrations used for
histochemical staining included Ki-67 1:200 (Abcam, Cambridge, MA),
phosphorylated Smad2 1:1000 (Cell Signaling, Danvers, MA), PTEN
1:50 (Cell Signaling), phosphorylated histone H3 1:500 (Upstate,
Billerica, MA), CD31 1:50 (Abcam), phosphorylatedMcl-1 1:500 (Santa
Cruz Biotechnology, Santa Cruz, CA). β-Galactosidase was stained
histochemically using proteinase K (20 μg/ml for 10 minutes at 37°C)
treatment of hydrated tissue sections for antigen retrieval and using
β-galactosidase antibody 1:2000 (Abcam). Terminal uridine deoxynucleo-
tidyl transferase dUTP nick end labeling (TUNEL) staining was per-
formed using the ApopTag Peroxidase In situ Apoptosis Detection
kit (Chemicon, Billerica, MA) to detect apoptotic cells. Statistical
significance was determined by two-tailed Student’s t tests (P ≤ .05).
Results
Tgfbr2ColTKOMice Exhibit Progression of Prostatic Tumorigenesis
Useful for Evaluating Experimental Therapeutics
The development of new murine models that more adequately
recapitulate the characteristics of human disease is needed to advance
preclinical testing of novel therapeutic agents and to increase the rate
of translation of new treatment regimens into validated clinical proto-
cols. However, no single model can mimic all facets of human dis-
ease. Thus, multiple models are used in this study to test the efficacy
of Sabutoclax in late-stage PCa. Transgenic mouse models have several
advantages to xenograft models in that mouse hosts have an intact im-
mune system and tumors result from stromal/epithelial interactions of
the same species. Therefore, a new long-term model of PCa progres-
sion was established by generating mice lacking stromal responsiveness
to TGF-β by tamoxifen-inducible conditional stromal knockout of
Tgfbr2 (Tgfbr2ColTKO). These mice develop normally without the early
lethality observed previously in Tgfbr2fspKO mice [34]. β-Galactosidase
staining (Figure 1) and Tgfbr2 recombination PCR (data not shown)
demonstrated, respectively, the activation of Cre-mediated recombina-
tion of the Rosa26 and floxed Tgfbr2 loci in these mice. By 17 weeks of
age, the Tgfbr2ColTKO mouse prostates develop PIN lesions (Figure 1)
throughout each of the anterior and dorsolateral lobes with 100% pen-
etrance. Examination of hematoxylin and eosin (H&E)–stained sections
revealed the presence of focal areas of prostate adenocarcinoma in
these mice (Figure 1). Areas of adenocarcinoma expanded throughout
the life of Tgfbr2ColTKO mice as indicated by H&E stained sections
Figure 1. Establishment of a prostate adenocarcinoma mouse
model by stromal knockout of Tgfbr2. Compared with (A) con-
trol Tgfbr2floxE2/floxE2/ColCre/Rosa26 (Tgfbr2ColTflox) control mice,
β-galactosidase staining of (B) Tgfbr2ColTKO/Rosa26 mouse prostate
stroma indicated Cre-mediated recombination of Tgfbr2. Representa-
tive images of H&E-stained paraffin-embedded tissue sections from
Tgfbr2ColTflox and Tgfbr2ColTKO mice indicate (C, D) development of
widespread PIN lesions with 100% penetrance by 17 weeks of age
in Tgfbr2ColTKO mice. (E) PIN lesions in 17-week-old Tgfbr2ColTKO mice
can be better appreciated at higher power. (F) By 58 weeks of age,
70%of Tgfbr2ColTKOmice develop further progression to focal lesions
of adenocarcinoma. Scale bar, 20 μm (A-C) and 10 μm (D-F).
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from 58-week-old mice. These data suggest that Tgfbr2ColTKO mice,
mimicking the stromal loss of TGF-β responsiveness found in human
disease, develop PCa through a paracrine manner.
A number of molecular features were examined in the Tgfbr2ColTKO
mice to determine the extent to which the progression of PCa in
these mice phenocopies human disease. Heterogeneous expression of
phosphorylated Smad2 was observed histochemically in the prostatic
stromal compartment of Tgfbr2ColTKO mice (Figure W1), similar to
our previous observations of Tgfbr2fspKO mice and human PCa spec-
imens [15,35]. There was a pronounced loss of the differentiation
marker, prostatic acid phosphatase (PAP), in areas of transformation
of Tgfbr2ColTKO prostates (Figure 2). Disorganization and depletion
of the basal cell layer was demonstrated through p63 localization, a
differentiation marker for basal cells. Further, Tgfbr2ColTKO mice had
a demonstrable loss of Pten expression in regions of epithelial hyper-
plasia. As a control, Tgfbr2ColTFlox prostates expressed PAP and Pten
in the luminal epithelia and p63 in the basal epithelia (Figure 2). The
loss of Pten expression suggested the potential for castrate resistance
[36]. To test for the castrate response of the Tgfbr2ColTKO mice, the
proliferative potential of the prostate glands were examined 4 days after
castration. Immediately after castration, the Tgfbr2ColTKO prostate
luminal epithelia maintained a high mitotic index (P = .01) and low
apoptosis levels (P = .03) as measured by the expression of phospho-
rylated histone H3 and TUNEL, respectively, in the luminal epithelial
cells compared with Tgfbr2ColTFlox mice (Figure 3A). Unlike in men,
the Tgfbr2ColTKO prostates maintain a high rate of proliferation inde-
pendent of castration status, modeling a paracrine castration resis-
tance model without a phase of regression. Although the etiology of
CRPC development in Tgfbr2ColTKO mice may not be found in man,
the histologic and molecular changes in the stromal and epithelial
compartments mimicked human CRPC.
Sabutoclax Treatment Restored Differentiation and
Reduced Tumor Size in Models of PCa
Sabutoclax is a recently developed Mcl-1 antagonist currently under-
going preclinical testing in several laboratories (see structure, Figure 3B).
To determine whether this drug would have efficacy on CRPC,
36-week-old male Tgfbr2ColTKO mice were treated with Sabutoclax
or vehicle. The H&E-stained sections of Tgfbr2ColTKO prostate treated
with Sabutoclax revealed increased differentiation as exhibited by re-
duction in the extent of PCa lesions and a more normal glandular
architecture (Figure 3C ). TUNEL staining further indicated the pres-
ence of significant apoptosis of prostatic epithelia in Sabutoclax-treated
Tgfbr2ColTKO mice compared with vehicle treatment (P ≤ .0001)
and significantly greater than wild-type C57BL/6 control mice as de-
termined by TUNEL positivity in the prostate (P≤ .0001; Figure 3, A
and C). Interestingly, Sabutoclax had no significant effect on the mi-
totic index of either wild-type or Tgfbr2ColTKO prostate. The data dem-
onstrated that Sabutoclax inhibited and reversed the PCa progression
phenotype of Tgfbr2ColTKO mice where castration had limited effect.
Human PCa xenograft models were used to test Sabutoclax efficacy
on castrate-resistant tumor growth. The castrate-resistant C4-2 PCa
cells were injected subcutaneously into nude mice and allowed to
form palpable tumors by 20 days after injection. Treatment of C4-2
tumor-bearing mice with Sabutoclax for 1 week resulted in a significant
reduction in tumor volume compared with vehicle-treated mice with-
out a significant change in mouse body weight (Figure 4A). Histologic
examination of these xenografts did not suggest changes in differen-
tiation of the C4-2 xenografts other than gross size. However, the
immunohistochemical staining suggested reduced expression of Mcl-1
and the proliferation marker, Ki-67 (Figure 4B). Further, quantitation
of TUNEL staining indicated a significant increase in apoptosis after
Sabutoclax treatment (P = .027; Figure 4C ). Together, transgenic
mouse and human xenograft CRPC models provided complementary
support on the role of Sabutoclax in reducing tumor burden.
Sabutoclax Treatment Reduced c-Met Signaling and
PCa Xenografts Growth in Bone
HGF/c-Met signaling is demonstrated to regulate Mcl-1 expression
and associated with PCa metastatic bone growth [37,38]. So, to test
whether Sabutoclax affects c-Met signaling, we initially examined its
role on human bone metastatic ARCAPM cells, previously reported
Figure 2. Human hallmarks of PCa are identified in the Tgfbr2ColTKO mouse prostate glands. The Tgfbr2ColTKO mice have immuno-
histochemical evidence of the loss of PAP expression in the epithelia, disorganization of the basal cell layer as indicated by p63 staining,
and epithelial down-regulation of Pten, compared with control Tgfbr2ColTflox mice. Further, Mcl-1 expression was localized in the epithelia
of Tgfbr2ColTKO prostates and was absent in Tgfbr2ColTflox tissues. Black and green arrowheads indicate cells expressing or not expressing
the indicated markers, respectively. Scale bar, 10 μm.
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Figure 4. Sabutoclax reduced the size of established xenografted human C4-2 PCa xenograft tumors. (A) Significant tumor volume
reduction of the subcutaneous xenografts was observed by Sabutoclax (SBX) treatment compared with vehicle-treated control mice,
without any significant impact on mouse’s body weight (n = 8, P = .03). (B) By immunohistochemical staining, the tumors showed
reduction in phosphorylated Mcl-1, Ki-67, and TUNEL expression after SBX treatment compared with vehicle control. (C) Quantitation of
TUNEL staining indicated a significant elevation of apoptosis with SBX treatment compared with vehicle control (P = .027).
Figure 3. Sabutoclax, a novel broad-spectrum Bcl-2 family antagonist limits the prostate tumor and PIN phenotype in castrate-resistant
Tgfbr2ColTKO mice. (A) Quantitation of positively stained cells undergoing mitosis (by histone H3 localization) and apoptosis (by TUNEL
localization) in wild-type (WT) and Tgfbr2ColTKO (KO) mice that were left intact, castrated for 4 days, or treated with Sabutoclax (SBX, n =
20) are indicated. Significant differences were observed in the following comparisons: proliferative index of intact WT and KO prostates in
each of the conditions (P < .01), as well as the apoptotic index of the KO prostates comparing SBX treatment to either intact or castrate
conditions (P < .0001). Elevated apoptosis was observed in SBX-treated KO compared with WT prostates (P = .00006). (B) The chemical
structure of SBX is indicated. (C) Tgfbr2ColTKO mice (36 weeks old), as well as similarly aged wild-type C57BL/6 control mice, were
treated with vehicle or SBX for 2 weeks. H&E staining suggested that the Tgfbr2ColTKO prostate tumors were more differentiated in the
SBX-treated mice compared with vehicle control-treated mice. TUNEL-positive apoptotic prostate cells were more abundant in SBX-treated
Tgfbr2ColTKO comparedwith similarly treated Tgfbr2ColTFlox and vehicle-treatedmice. Little changewas observed inmorphology or apoptosis
in vehicle- and SBX-treated wild-type C57BL/6 mice.
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to have autocrine c-Met activity [39]. Western blot analysis suggested
the loss in phosphorylated c-Met expression in ARCAPM cells by
24 hours of treatment, with little change in total c-Met in the same time
frame (Figure 5A). Forty-eight hours of Sabutoclax treatment reduced
total Mcl-1 expression by 50% of untreated control. Concomitant up-
regulation of cleaved caspase 3 provided an independent measure apop-
tosis induced by Sabutoclax in the same period. Phosphorylated c-Met
histochemical localization was performed on longer-term Sabutoclax
treatment of Tgfbr2ColTKO mice and C4-2 subcutaneous xenografts
in nude mice. Sabutoclax reduced phosphorylated c-Met expression in
Tgfbr2ColTKO prostatic tissues and the C4-2 xenografts compared with
control mouse tissues (Figure 5B). Observed decrease in c-Met activa-
tion, concurrent with Sabutoclax treatment, suggested autocrine and
paracrine regulation of c-Met signaling by Mcl-1.
Effects of Sabutoclax on c-Met signaling, commonly associated with
in human metastatic PCa, supported further testing in a model of
PCa in a common metastatic site—the bone. A xenograft model of
PCa growth in bone was established by bilateral intratibial injection
of ARCaPM-luc PCa cells into male nude mice. Longitudinal luciferase
imaging revealed the establishment and growth of the ARCaPM-luc
tumors. Treatment with Sabutoclax after 1 week significantly reduced
the size of the bone lesion compared with mice treated with vehicle
alone (P = .0006). Reduction in the extent of the bone tumors was
verified by in vivo luciferase detection of the ARCaPM-luc bone xeno-
grafts (Figure 5C ). Thus, Sabutoclax downregulated proliferation of
both the C4-2 and ARCaPM xenografts, concomitant with increased
apoptosis, as evidenced by dramatic tumor size reduction, similar to
that observed in Tgfbr2ColTKO transgenic mice. Together, it suggested
that antagonism of Mcl-1 and other antiapoptotic Bcl-2 family proteins
by Sabutoclax may be effective to target the growth of both primary
and metastatic CRPCs.
Sabutoclax Sensitized PC-3 Cells to Docetaxel-Induced
Apoptosis In Vitro and In Vivo
Mortality from PCa most commonly results from the resistance
to chemotherapy with docetaxel. To evaluate the ability of the pan-
active Bcl-2 inhibitor Sabutoclax to synergize with docetaxel for the
treatment of human PCa, we used the Chou-Talalay method for
synergy analysis [28,40]. This model is able to take into account the
nonuniform dose-response curves that we had previously observed in
single-agent dosing experiments [30]. For these tests, we plated a three-
log order dose-response curve for each of the compounds individually
as well as in a ratio combination on a single 96-well plate with each dose
collected in triplicate. At 72 hours after administration of the drug to
the plated androgen receptor–deficient PC-3 cells, the relative ATP con-
centration in each well was measured with respect to an internal DMSO
Figure 5. Reduction in phosphorylated c-Met expression and ARCaPM prostate tumor growth in bone by Sabutoclax treatment. (A) Western
blot of ARCaPM cells treated with Sabutoclax (SBX) for a time course of 0 to 48 hours indicating the expression of phosphorylated and
total c-Met, Mcl-1, and β-actin. In the same time frame, elevated cleaved caspase 3 expression was observed with SBX treatment.
(B) Immunohistochemical staining of Tgfbr2ColTKO prostates and C4-2 subcutaneous xenografts indicated a reduction in phosphorylated
c-Met expression compared with vehicle-treated control tissues. (C) Intratibial inoculation of ARCaPM-LUC cells were detected by in vivo
luciferase imaging. The representative images shown were taken after 2 weeks of treatment with vehicle or SBX. Significant reduction
of luciferase signal was observed with SBX treatment (n = 6, P = .0006). Postacquisition histochemical analysis confirmed reduced tumor
size and repair of the bone lesion.
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control as a proxy for cell viability. The resultant dose-response curves
(Figure 6A) were used to identify the respective ED50 and ED90 values
for each drug individually and in combination. In addition, these curves
were analyzed to calculate the CI value for each cell line [41]. Using the
CI model of drug combination, CI = 1 indicates an additive effect
whereas CI < 1 indicates synergy and CI > 1 indicates antisynergy.
Our analysis identified strong synergy of Sabutoclax and docetaxel
treatment (Figure 6B).
To determine whether the synergy observed in vitro could be repli-
cated in vivo, we tested the compounds individually and in combination
for their ability to suppress growth of PC-3mouse xenograft tumors.We
first established the dose dependence of Sabutoclax (2, 5, and 10 mg/kg
three times weekly) in the PC-3 xenograft model. The three groups of
mice had a strong dose-dependent response (Figure 6C) and exhibited
minimal weight loss over the course of the study. From this initial
analysis, we chose a three-time weekly dose of 2 mg/kg Sabutoclax and
a once-weekly dose of 12.5 mg/kg docetaxel for the combination study.
Control injections without drug were administered to the control group
and to each of the single-agent groups to simulate stress from the total
number of injections administered to the combination group. Mouse
weight and tumor size was tracked during the course of the treatment
(Figure 6D). A significant difference in tumor size was observed between
the Sabutoclax or docetaxel arms and the combination arm (P < .0001).
The observed in vitro and in vivo synergism resulting from the combina-
tion of Sabutoclax with docetaxel treatment established Sabutoclax as
an effective drug that should be further evaluated in clinical trials aimed
at improving treatments for chemotherapeutically resistant PCa.
Discussion
Treatment of PCa with cytotoxic chemotherapeutic agents to date
has largely been ineffective because of prevalent cellular resistance. In-
hibition of apoptosis by the overexpression of Mcl-1– and other anti-
apoptotic Bcl-2–related proteins constitutes a common mechanism for
PCa resistance to therapy [6]. Gossypol derivatives have been identified
and developed over the last several years as strong antagonists of Bcl-2–
related proteins, blocking their ability to inappropriately sequester
proapoptotic proteins when overexpressed [42,43]. Initial pharmaco-
dynamics and pharmacokinetic studies for Sabutoclax involving an
extensive panel of cancer cell lines have been previously published
and support the efficacy of Sabutoclax as both a single and combined
therapeutic agent [28,30,44]. Administration of Bcl-2 family antago-
nists, like Sabutoclax, may alleviate resistance by either directly acti-
vating mitochondrial-dependent apoptosis or restoring PCa sensitivity
to conventional therapeutic agents when used in combination. Indeed,
Figure 6. Synergistic cytotoxic activity of Sabutoclax (SBX) in combinationwith docetaxel (DTR). (A) In vitro dose-response curves of SBX (□),
DTR (○), and their 10:1 SBX/DTR combination (▴) exhibited ED50/ED90 values of 122 ± 12/196 ± 55 nM, 5.5 ± 0.4/23 ± 4 nM, and 1.3 ± 0.1/2.6 ± 0.3 nM, respectively. CI50 and CI90 values in CalcuSyn were 0.45 and 0.35, respectively. (B) ED50 isobologram of SBX and DTR synergy.
The ED50 values for seven combinations of SBX and DTR show a significant (P < .0001) deviation below the additive dotted line, which is
indicative of a synergistic combination. (C) In vivo SBX efficacy. Tumor growth curves show a dose-dependent reduction in tumor volume
to treatment with SBX 3 times weekly at 2, 5, and 10 mg/kg versus control. Each point is the mean ± SEM (n = 5) of the measured tumor
volume. The curves for the 5 and 10 mg/kg were each significantly different from the control (P = .0084 and P < .0001, respectively).
(D) In vivo efficacy of SBX and DTR combination. Tumor growth curves show the mean ± SEM (n = 6) of subcutaneous PC-3 xenografts
after treatment with DTR (12.5 mg/kg, weekly), SBX (2.0 mg/kg, three times weekly), and their combination. The combination is significantly
different (P < .0001) from either of the other three growth curves.
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initial pharmacodynamic and pharmacokinetic studies for Sabutoclax
involving an extensive panel of cancer cell lines have been previously
published and support the efficacy as a single and combined therapeutic
agent [28,44]. In short, the data from these experiments demonstrate
for the first time that Sabutoclax is effective at inhibiting tumor pro-
gression in transgenic, subcutaneous, and orthotopic mouse models
of human PCa. Further, Sabutoclax increased sensitivity to docetaxel
when used in combination.
We tested the hypothesis that treatment of prostate tumors with
Sabutoclax would result in inhibition of castrate-resistant prostate
tumor progression and perhaps contribute to tumor regression. The
development of new stromally targeted transgenic mouse models for
studying PCa was important in testing Sabutoclax efficacy on CRPC
and extends our understanding of the complex roles of the tumor
microenvironment on the progression of PCa [45]. Previously, we
demonstrated that Tgfbr2fspKO mice develop PIN lesions that, after
tissue rescue, could progress to adenocarcinoma [10,11]. However,
the Tgfbr2fspKO mice had limited usefulness in studies of PCa progres-
sion as they died at 6 to 8 weeks of age [11,34]. In contrast, untreated
and tamoxifen-induced Tgfbr2ColTKO mice are healthy and live to at
least 60 weeks of age, which is advantageous for their use in long-term
studies of PCa progression and therapeutic investigation in aging adult
mice. Tgfbr2ColTKO mice develop widespread PIN and foci of prostatic
adenocarcinoma, with castrate-resistant growth. Importantly, unlike
other models of castrate-resistant growth (or that generally observed
in men), the Tgfbr2ColTKO mice do not exhibit an initial prostate re-
gression after castration. Thus, surgical castration of Tgfbr2ColTKO mice
is not necessary to push the prostatic lesions to castrate resistance (pro-
viding a potential savings in time and labor in future preclinical murine
studies of CRPC) as well as enabling the use of these mice to model
the effects of the entire range of clinically used androgen-deprivation
therapies (chemical and/or surgical castration). The Tgfbr2ColTKO mice
do exhibit other characteristics of human PCa as exemplified by hetero-
geneous expression of stromal phosphorylated Smad2, similar to our
reported observations in Tgfbr2fspKO mice and human PCa tissues
[15]. Further, the loss of PTEN expression in areas of epithelial hyper-
plasia of Tgfbr2ColTKO prostatic glands recapitulates a key aspect of
human PCa progression, demonstrated to be a prognostic predictor
for the development of CRPC (as defined by PSA biochemical recur-
rence) in patients [46]. Unlike epithelial-targeted PCa models, the
transgenic targeting of stromal cells allows for heterogeneous develop-
ment of multifocal tumors, to arguably better mimic human PCa. The
Tgfbr2ColTKO model supports the concept that castrate-resistant pros-
tate cells may reside in the absence of androgen receptor antagonism
[36]. Together, these data validate the use of Tgfbr2ColTKO mice as
an in vivo model system for testing therapeutic agents targeting CRPC.
The tumor-bearing mouse models of human PCa used in this study
had diminished measures of cancer progression in Sabutoclax-treated
animals. Administration of Sabutoclax reduced the severity of the PIN
phenotype and restored a more normal prostatic glandular architecture
to the prostates of Tgfbr2ColTKO transgenic mice, yet had a lesser apop-
totic effect on benign tissues from C57BL/6 mice. The restricted speci-
ficity of action for Sabutoclax on early-initiated and progressed prostatic
tumors is attributed to the selective over expression of Mcl-1 and related
antiapoptotic Bcl-2 family proteins in cancer tissues. The mixture of
benign and heterogeneous cancer tissues in Tgfbr2ColTKO prostates
acted as an internal control. Sabutoclax was also effective in reducing
the size and volume of subcutaneous tumors grown from human
C4-2 PCa cells in nude mice, while being well tolerated by these mice
without appreciable weight loss, as previously suggested in other tumor
bearing mouse models [24,30]. The regression of the C4-2 tumors is
readily attributed to the combined decrease in proliferation (Ki-67
staining) and increased apoptosis sensitivity (MCL-1 staining) caused
by Sabutoclax treatment. Finally, Sabutoclax was effective in reducing
the growth and extent of tibial bone destruction by ARCaPM orthotopic
xenografts. A similar reduction in bone lesions was reported in early
results from ongoing clinical studies that used the c-Met/VEGFR2
antagonist, XL184 [47]. Inhibition of tumor progression by Sabutoclax
for both C4-2 and ARCaPM human prostatic tumor xenografts sub-
cutaneously and intratibially is known to grow in a castrate-resistant
manner [48,49], to support Sabutoclax efficacy as a single agent in
the clinical treatment of advanced and metastatic PCa.
Owing to the recent characterization of Mcl-1 as a key regulator of
apoptosis during mitotic progression [50], we sought to determine
whether an Mcl-1–targeting therapeutic agent, such as Sabutoclax,
could potentiate docetaxel action. Docetaxel is a known microtubule
stabilizer and first-line chemotherapeutic agent for the treatment of
PCa. PC-3 cells are known to be temporally insensitive to docetaxel in
that they undergo growth arrest with a significant delay in onset of cell
death [51]. Our studies with Sabutoclax as single agent and in com-
bination with docetaxel demonstrated a significant synergistic benefit
for the treatment of androgen-resistant, docetaxel-refractive PC-3 cells
in culture and xenograft models. These results are supported by a recent
study in which melanoma was sensitized synergistically to apoptotic cell
death by treatment with Sabutoclax and Ad-mda7/IL-24 [30,52].
These data support Sabutoclax as a powerful component of combina-
torial therapy for PCa. We noted that phosphorylation of c-Met was
reduced in tumors treated with Sabutoclax, correlating with increased
apoptosis. The mechanisms underlying these observations remain to be
determined but could reflect a downstream consequence of Sabutoclax-
mediated caspase activation or other elements of the apoptotic program
in reversing both docetaxel resistance and c-Met signaling. However,
we cannot exclude the possibility that Sabutoclax may in fact be a direct
regulator of the activation pathway of c-Met—the receptor for HGF.
The inhibition of c-Met phosphorylation by Sabutoclax in Tgfbr2ColTKO
mice suggests an inhibition of paracrine HGF signaling, whereas that
observed in ARCAPM cells is autocrine. The relationship between
Mcl-1 and c-Met signaling, and hence whether Mcl-1 impinges on
stromal TGF-β signaling, which is known to negatively regulate HGF
production [11,12], deserves further exploration in future biochemical
and signal transduction studies.
In summary, administration of the pan-active Bcl-2 family antagonist,
Sabutoclax, was sufficient to inhibit tumor progression in models of
advanced PCa. The data support a potential role in blocking the feed-
back loop between Mcl-1 and c-Met signaling. Synergy of Sabutoclax
with docetaxel supports future testing of its efficacy in combination
therapies for multiple advanced cancers, besides PCa, that develop
taxol resistance.
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Figure W1. Immunohistochemical staining for phosphorylated
Smad2 is uniformly expressed in the human benign and PCa epi-
thelia. However, phosphorylated Smad2 expression is hetero-
geneously downregulated in the PCa-associated stroma (green
arrow) and retained in the benign stromal compartment. Similarly,
we observed heterogeneous down-regulation of phosphorylated
Smad2 in Tgfbr2ColTKO mouse prostate sections (top right). Scale
bar, 10 μm.
